Heritable coagulopathies in pregnancy

Obstetrical and Gynecological Survey

Volumn 54, Issue 12, 1999, Pages 754-765

  Lockwood, Charles J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ACTIVATED PROTEIN C RESISTANCE; ANTITHROMBIN III DEFICIENCY; COMORBIDITY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; GENETIC SUSCEPTIBILITY; HERITABILITY; HUMAN; HYPERHOMOCYSTEINEMIA; LUNG EMBOLISM; MALE; PREECLAMPSIA; REVIEW; RISK ASSESSMENT; STILLBIRTH; THROMBOEMBOLISM; VERTICAL TRANSMISSION;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HEPARIN; HUMANS; HYPERHOMOCYSTEINEMIA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; SERINE PROTEINASE INHIBITORS; THROMBOMODULIN;

EID: 0032736422     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-199912000-00004     Document Type: Review

References (83)

1. Girling J, de Swiet M. Inherited thrombophilia and pregnancy. Curr Opin Obstet Gynecol 1998;10:135-144.
2. Preston FE, Rosendaal FR, Walker ID et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348:913-916.
3. Dekker GA, de Vries JIP, Doelitzch PM et al. Underlying disorders associated with severe early onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-1048.
4. Lindoff C, Ingermarsson I, Martinsson G et al. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 1997;176:457-460.
5. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71: 1-8.
6. Rapaport SJ. Regulation of the tissue factor pathway. Ann NY Acad Sci 1991;614:51-62.
7. Lockwood CJ, Bach R, Guha A et al. Amniotic fluid contains tissue factor, a potent initiator of coagulation. Am J Obstet Gynecol 1991;165:1335-1341.
8. Lockwood CJ, Nemerson Y, Guller S et al. Progestational regulation of human endometrial stromal cell tissue factor expression during decidualization. J Endocrinol Metab 1993; 76:231-236.
9. Runic R, Schatz F, Krey L, Demopoulos R et al. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception. J Clin Endocrinol Metab 1997;82:1983-1988.
10. Dennington PM, Berndt MC. The thrombin receptor. Clin Exp Pharmacol Physiol 1994;21:349-358.
11. Seiler SM. Thrombin receptor antagonists. Semin Thromb Hemost 1996;22:223-232.
12. Preissner KT, De Boer H, Pannekoek H et al. Thrombin regulation by physiological inhibitors: The role of vitronectin. Semin Thromb Hemost 1996;22:165-172.
13. III CR, Rouslahti E. Association of thrombin-antithrombin III complex with vitronectin in serum. J Biol Chem 1985;260: 15610-15615.
14. Preissner KT, Zwicker L, Muller-Berghaus G. Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum. Biochem J 1987;243:105-111.
15. de Boer HC, de Groot PG, Bouma BN et al. Ternary vitronectin-thrombin-antithrombin III complexes in human plasma: Detection and mode of association. J Biol Chem 1993;257: 3243-3248.
16. Delorme MA, Burrows RF, Ofosu FA et al. Thrombin regulation in mother and fetus during pregnancy. Semin Thromb Hemost 1992;18:81-90.
17. Esmon CT. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993;70:29-35.
18. Bombell T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997;77:408-423.
19. Girard TJ, Warren LA, Novotny WF et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989;338:518-520.
20. Warr TA, Warn-Cramer BJ, Rao LV et al. Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiologic variables. Blood 1989;74:201-206.
21. Novotny WF, Brown SG, Miletich JP et al. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991;78:387-393.
22. Schatz F, Lockwood CJ. Progestin regulation of plasminogen activator inhibitor type-1 in primary cultures of endometrial stromal and decidual cells. J Clin Endocrinol Metab 1993;77: 621-625.
23. Estelles A, Gilabert J, Anar J et al. Changes in plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989;74:1332-1338.
24. van Meijer, Gebbink RK, Preissner KT et al. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1). FEBS Letters 1994;352:342-346.
25. Seiffert D, Wagner NN, Loskutoff DJ. Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor. J Cell Biol 1990;111:1283-1291.
26. Preissner KT, Holzhuter S, Justus C et al. Identification and partial characterization of platelet vitronectin: Evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 1989;74:1989-1996.
27. Salonen EM, Vaheri A, Pollanen J et al. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 1989;264:6339-6343.
28. Ehrlich HJ, Klein Gebbink R et al. Alteration of serpin specificity by a protein cofactor: Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990;265:13029-13035.
29. Stringer HAR, van Swieten P, Heijnen HFG et al. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolytic resistance. Studies with thrombin generated in the Chandler loop. Arterioscler Thromb 1994;14: 1452-1458.
30. Preissner KT, De Boer H, Pannekoek H et al. Thrombin regulation by physiological inhibitors: The role of vitronectin. Semin Thromb Hemost 1996;22:165-172.
31. Lockwood CJ, Rand JH. The immunobiology and obstetrical consequences of antiphospholipid antibodies. Obstet Gynecol Surv 1994;49:432-441.
32. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
33. Voorberg J, Roeise J, Koopman R et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg 506 of factor V. Lancet 1994;343:1535-1536.
34. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-1538.
35. Ridker PM, Miletich JP, Hennekens CH et al. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. J Am Med Assoc 1997:277:1305-1307.
36. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995:346:1133-4.
37. Koster T, Rosendaal FR, de Ronde H et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993;342:1503-1506.
38. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330: 517-522.
39. de Stefano V, Leone G. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologia 1995;80:344-356.
40. Vandenbrocke JP, Koster T, Breit E et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-1457.
41. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FR et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestogen. Lancet 1995;346:1593-1596.
42. Dizon-Townson DS, Nelson LM, Jang H et al. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep-vein thrombosis. Am J Obstet Gynecol 1997;176:883-886.
43. Friederich PW, Sanson BJ, Simioni P et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women.implications for prophylaxis. Ann Intern Med 1996: 125:955-960.
44. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995;173:210-213.
45. Hallak M, Senderowicz J, Cassel A et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997;176:889-893.
46. Brenner B, Mandel H, Lanir N et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997:97:551-554.
47. Dizon-Townson DS, Meline L, Nelson LM et al. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol 1997:177:402-405.
48. Dizon-Townson DS, Nelson LM, Easton K et al. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996;175:902-905.
49. Thorarensen O, Ryan S, Hunter J et al. Factor V Leiden mutation.an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis. Ann Neurol 1997;42: 372-375.
50. Girling JC, de Swiet M. Thromboembolism in pregnancy: An overview. Curr Opin Obstet Gynecol 1996;8:458-463.
51. Cavenagh JD, Colvin BT. Guidelines for the management of thrombophilia. Postgrad Med J 1996;72:87-94.
52. Rao AK, Sheth S, Kaplan R. Inherited hypercoagulable states. Vase Med 1997;2:313-320.
53. Lane DA, Bayston T, Olds RJ et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997;77:197-211.
54. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: Review of 404 cases. Thromb Haemost 1987:58:1094.
55. Tait RC, Walker ID, Perry DJ et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994:87: 106-112.
56. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987;317:991-996.
57. Winkler UH, Zierleyn JP, Schulte H et al. Routine screening for coagulation inhibitors prior to prescribing the pill: Prevalence data from a large cohort of German pill starters. J Contracept Reprod Health Care 1996;1:47-52.
58. Allaart CF, Poort SR, Rosendaal FR et al. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993;341:134-138.
59. Gouault-Heilmann M, Leroy-Matheron C, Levent M. Inherited protein S deficiency. Clinical manifestations and laboratory findings in 63 patients. Thromb Res 1994;76:269-279.
60. Engresser L, Broekmans AW, Briet E et al. Hereditary protein S deficiency: Clinical manifestations. Ann Intern Med 1987; 106:677-682.
61. Sanson BJ, Friederich PW, Simioni P et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996;75:387-388.
62. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996;87:3531-3544.
63. Molloy AM, Daly S, Mills JL et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: Implications for folate intake recommendations. Lancet 1997;349:1591-1593.
64. van der Put NM, Eskes TK, Blom HJ. Is the common 677C->T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. Q J Med 1997;90:111-115.
65. de Vries JI, Dekker GA, Huijgens PC et al. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997;104:1248-1254.
66. Wouters MG, Boers GH, Blom HJ et al. Hyperhomocystinemia: A risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993;60:820-825.
67. den Heijer M, Koster T, Blom HJ et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-762.
68. Poort SR, Rosendaal FR, Reitsma PH et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
69. Margaglione M, Brancaccio V, Giuliani N et al. Increased risk for venous thrombosis in carriers of the prothrombin G (A20210 gene variant). Ann Intern Med 1998;129:89-93.
70. Rouse DJ, Goldenberg RL, Wenstrom KD. Antenatal screening for factor V Leiden mutation: a critical appraisal. Obstet Gynecol 1997;90:848-851.
71. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574.
72. Wessler S, Gitel SN. Heparin: New concepts relevant to clinical use. Blood 1979;53:525-544.
73. Ginsberg J, Hirsh J, Turner DC et al. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989;61:197-203.
74. Ginsberg J, Kowalchuk G, Hirsh J et al. Heparin therapy during pregnancy. Risks to the fetus and mother. Arch Intern Med 1989;149:2233-2236.
75. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
76. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816-1828.
77. Griffith GC, Nichols G Jr, Asher JD et al. Heparin osteoporosis. J Am Med Assoc 1965;193:85-88.
78. Hull RD, Raskob GE, Rosenbloom D et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-1264.
79. Hull R, Delmore T, Carter C et al. Adjusted subcutaneous heparin versus Warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982:306;189-194.
80. Lensing AW, Prins MH, Davidson BL et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-607.
81. Howard PA. Dalteparin: A low-molecular-weight heparin. Ann Pharmacother 1997;31:192-203.
82. Raskob GE. Low molecular weight heparin, heparin, and warfarin. Curr Opin Hematol 1995;2:372-379.
83. Fejgin MD, Lourwood DL. Low molecular weight heparins and their use in obstetrics and gynecology. Obstet Gynecol Surv 1994;49:424-431.